ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0654

Lymphatic Dysfunction and Immune Activation in Lupus

william ambler1, Madhavi Somaraju1, JiHyun Sim1, Ethan Seltzer1, Noa Schwartz2, Ecem Sevim3, Doruk Erkan1, Jinyeon Shin4, Rahgu Kataru4, Babak Mehrara5 and theresa Lu1, 1Hospital for Special Surgery, New York, NY, 2Albert Einstein College of Medicine, New York, NY, 3Montefiore Medical Center - Wakefield Campus, New York, NY, 4Memorial Sloan Kettering, New York, NY, 5Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering, New York, NY

Meeting: ACR Convergence 2022

Keywords: Animal Model, Monocytes/macrophages, skin, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Systemic lupus erythematosus is a prototypic autoimmune disease in which patients frequently have photosensitivity. Exposure to ultraviolet radiation (UVR) causes the eruption of cutaneous lesions and can induce systemic disease flare. The lymphatic system removes fluid, soluble molecules, and cells from the skin and communicates with the immune system via draining lymph node. Dysfunctional lymphatics have been shown to exacerbate acute inflammation and to alter draining lymph node responses. Lymphatic flow is decreased after viral infection and is dependent on IFN-I signaling and IFN-I signaling is important in lupus pathophysiology. We thus hypothesized that lymphatics are dysfunctional in lupus and contribute to photosensitivity. The purpose of this study is to investigate lymphatic function in patients with lupus and murine lupus models as well as to assess the immunologic consequences of manipulating lymphatics.

Methods: We assessed lymphatics in patients with lupus by performing immunohistochemistry of skin biopsies. Murine lupus models were used to assess and manipulate lymphatics in vivo. MRL/lpr and an inducible model using chronic epicutaneous application of imiquimod (IMQ) on B6 mice were used. Lymphatic flow was increased using manual lymphatic drainage (MLD) or by using tamoxifen-treated B6 PTENfl/fl Flt4ERT2 mice (LECPTEN) with enhanced lymphatics. Lymphatic flow was examined in murine lupus models by assessing Evan’s blue retention in the skin at 24 hours after injection. Skin and draining lymph node responses were investigated by flow cytometric analysis after tissue digestion.

Results: Patients with lupus have dilated cutaneous lymphatics, consistent with poor lymphatic flow. Both MRL/lpr and IMQ lupus model mice had reduced lymphatic drainage compared to healthy controls after exposure to UVR. Improving lymphatic flow with MLD of MRL/lpr and IMQ lupus model mice or in IMQ-treated LECPTEN mice reduced cutaneous photosensitivity, as evidenced by decreased ear swelling and reduced immune cell infiltration. Furthermore, improving lymphatic flow reduced lymph node B cell responses with decreased germinal center B cells and plasmablasts. Mechanistically, improving lymphatic flow reduced B cell responses by acting on a lymph node fibroblastic reticular cell (FRC) CCL2-monocyte axis that we have previously shown to limit B cell responses.

Conclusion: Together, our results demonstrate that lupus skin is characterized in part by lymphatic dysfunction, and that this dysfunction contributes to both cutaneous photosensitivity and draining lymph node B cell responses. In lymph nodes, improved lymphatic flow limits B cell responses by acting on a FRC CCL2-monocyte axis that we have previously established. Our data suggest that dysfunctional lymphatic flow is a contributing factor to lupus pathophysiology and points to lymphatic function as a therapeutic target.


Disclosures: w. ambler, None; M. Somaraju, None; J. Sim, None; E. Seltzer, None; N. Schwartz, None; E. Sevim, None; D. Erkan, None; J. Shin, None; R. Kataru, None; B. Mehrara, PureTech corp, Regeneron corp, Pfizer; t. Lu, None.

To cite this abstract in AMA style:

ambler w, Somaraju M, Sim J, Seltzer E, Schwartz N, Sevim E, Erkan D, Shin J, Kataru R, Mehrara B, Lu t. Lymphatic Dysfunction and Immune Activation in Lupus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lymphatic-dysfunction-and-immune-activation-in-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lymphatic-dysfunction-and-immune-activation-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology